Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy.

MLA

Liang, Ming-Juan, et al. “Efficacy and Safety of Switching from Brand-Name to Domestic Generic Levetiracetam in Children with Epilepsy.” Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics, vol. 24, no. 3, Mar. 2022, pp. 285–89. EBSCOhost, https://doi.org/10.7499/j.issn.1008-8830.2111033.

APA

Liang, M.-J., Qiu, W.-F., Zhang, J.-W., Li, X.-P., Shi, G.-A., Zhai, Q.-X., Zhang, Y.-X., & Chen, Z.-H. (2022). Efficacy and safety of switching from brand-name to domestic generic levetiracetam in children with epilepsy. Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics, 24(3), 285–289. https://doi.org/10.7499/j.issn.1008-8830.2111033

Chicago

Liang, Ming-Juan, Wei-Feng Qiu, Jing-Wen Zhang, Xue-Ping Li, Gang-An Shi, Qiong-Xiang Zhai, Yu-Xin Zhang, and Zhi-Hong Chen. 2022. “Efficacy and Safety of Switching from Brand-Name to Domestic Generic Levetiracetam in Children with Epilepsy.” Zhongguo Dang Dai Er Ke Za Zhi = Chinese Journal of Contemporary Pediatrics 24 (3): 285–89. doi:10.7499/j.issn.1008-8830.2111033.